Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METRO steroid discontinuation study in FDG-PET/CT-negative idiopathic retroperitoneal fibrosis
2024-514353-30-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of prednisone and prednisolone in Idiopathic retroperitoneal fibrosis (RPF), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Cumulative idiopathic retroperitoneal fibrosis relapse rate at month 21. Planned start Nov 2022; status: authorised.
02
Drugs
prednisoneprednisolone
03
Conditions
Idiopathic retroperitoneal fibrosis (RPF)
Beyond the preview
Go deeper on 2024-514353-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514353-30-00.